[go: up one dir, main page]

EP3573614C0 - PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY

Info

Publication number
EP3573614C0
EP3573614C0 EP18702961.6A EP18702961A EP3573614C0 EP 3573614 C0 EP3573614 C0 EP 3573614C0 EP 18702961 A EP18702961 A EP 18702961A EP 3573614 C0 EP3573614 C0 EP 3573614C0
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compositions
combination therapy
therapy
combination
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18702961.6A
Other languages
German (de)
French (fr)
Other versions
EP3573614B1 (en
EP3573614A1 (en
Inventor
Corinne Foucart
Robert Walczak
Carole Belanger
Benoît Noel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of EP3573614A1 publication Critical patent/EP3573614A1/en
Application granted granted Critical
Publication of EP3573614B1 publication Critical patent/EP3573614B1/en
Publication of EP3573614C0 publication Critical patent/EP3573614C0/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP18702961.6A 2017-01-27 2018-01-29 Pharmaceutical compositions for combination therapy Active EP3573614B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17305094 2017-01-27
EP17305268 2017-03-13
EP17190723 2017-09-12
PCT/EP2018/052159 WO2018138352A1 (en) 2017-01-27 2018-01-29 Pharmaceutical compositions for combination therapy

Publications (3)

Publication Number Publication Date
EP3573614A1 EP3573614A1 (en) 2019-12-04
EP3573614B1 EP3573614B1 (en) 2024-11-20
EP3573614C0 true EP3573614C0 (en) 2024-11-20

Family

ID=61157183

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18702961.6A Active EP3573614B1 (en) 2017-01-27 2018-01-29 Pharmaceutical compositions for combination therapy

Country Status (16)

Country Link
US (2) US11033534B2 (en)
EP (1) EP3573614B1 (en)
JP (1) JP7224294B2 (en)
KR (1) KR102537043B1 (en)
CN (1) CN110198708B (en)
AU (1) AU2018212614B2 (en)
CA (1) CA3046158A1 (en)
CO (1) CO2019008103A2 (en)
IL (1) IL267703B (en)
MX (1) MX392199B (en)
MY (1) MY203981A (en)
NZ (1) NZ755197A (en)
PH (1) PH12019501301A1 (en)
SG (1) SG11201906041QA (en)
WO (1) WO2018138352A1 (en)
ZA (1) ZA201905510B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513762A (en) * 2016-04-11 2019-05-30 ジェンフィGenfit Method of treating cholestasis and fibrosis
EA201991990A1 (en) * 2017-02-24 2020-04-07 Женфит PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
CN110025621A (en) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) Tizoxanide and Nitazoxanide application in preparing anti-inflammatory drugs
US12208087B2 (en) * 2019-04-09 2025-01-28 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
JP2022528727A (en) * 2019-04-12 2022-06-15 ジェンフィット Nitazoxanide and thiazolide for use in the treatment of diseases associated with oxidative stress
KR102199640B1 (en) * 2020-01-06 2021-01-07 브렉소젠 주식회사 Composition For Promoting Production of Stem Cell-derived Exosomes and Increasing Stemness comprising Lanifibranor
JP7337317B2 (en) * 2019-10-23 2023-09-04 カゴメ株式会社 Food composition for activating nuclear receptors and method for producing the same
AU2020376223A1 (en) * 2019-10-28 2022-06-02 Genfit Combination therapy having antioxydant properties
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022051323A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
CN114044761B (en) * 2021-02-24 2022-05-17 成都贝诺科成生物科技有限公司 Novel nitrothiazole derivative and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
US8785442B2 (en) * 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
CN110152000A (en) 2011-03-02 2019-08-23 J·深塔格 Composition for the treatment of hepatic steatosis alone or in the treatment of hepatic steatosis with hepatitis C virus infection

Also Published As

Publication number Publication date
PH12019501301A1 (en) 2019-12-11
JP7224294B2 (en) 2023-02-17
US11033534B2 (en) 2021-06-15
MX2019008917A (en) 2019-12-09
ZA201905510B (en) 2023-03-29
MX392199B (en) 2025-03-21
CN110198708B (en) 2022-09-20
BR112019015406A2 (en) 2020-05-19
JP2020506920A (en) 2020-03-05
US12053456B2 (en) 2024-08-06
IL267703A (en) 2019-08-29
WO2018138352A1 (en) 2018-08-02
NZ755197A (en) 2025-08-29
SG11201906041QA (en) 2019-08-27
IL267703B (en) 2022-05-01
US20190388398A1 (en) 2019-12-26
EP3573614B1 (en) 2024-11-20
KR102537043B1 (en) 2023-05-25
US20210275504A1 (en) 2021-09-09
EP3573614A1 (en) 2019-12-04
KR20190108141A (en) 2019-09-23
MY203981A (en) 2024-07-27
CO2019008103A2 (en) 2019-08-20
AU2018212614A1 (en) 2019-06-27
AU2018212614B2 (en) 2024-02-01
CN110198708A (en) 2019-09-03
CA3046158A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
EP3280421A4 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
EP3573614C0 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
ZA201906613B (en) Pharmaceutical compositions for combination therapy
EP3368084A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL ADMINISTRATION
EP3548000A4 (en) PHARMACEUTICAL COMPOSITIONS OF ATROPINE
MA41265A (en) COMPOSITIONS FOR THE ADMINISTRATION OF ILÉO-JEJUNAL DRUGS.
MA50541A (en) PHARMACEUTICAL FORMULATIONS
DK3253382T3 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
MA54716A (en) REDUCTION OF THE VISCOSITY OF PHARMACEUTICAL FORMULATIONS
DK3655038T3 (en) PHARMACEUTICAL COMPOSITION
MA46867A (en) PHARMACEUTICAL FORMULATIONS
MA42303A (en) PHARMACEUTICAL FORMULATIONS
EP3310439A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS
EP3463345A4 (en) PHARMACEUTICAL COMBINATIONS
HUE059584T2 (en) Pharmaceutical preparation for the treatment of anemia
DK3583943T3 (en) PHARMACEUTICAL COMPOSITION
MA49837A (en) PHARMACEUTICAL COMPOSITIONS
IL304109A (en) Pharmaceutical compositions comprising safinamide
EP3318259A4 (en) STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
MA47502A (en) PHARMACEUTICAL COMBINATIONS TO TREAT CANCER
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
SMT202400478T1 (en) PHARMACEUTICAL COMPOSITION
DK3773595T3 (en) Pharmaceutical anticancer compositions for combination therapy
EP3651800A4 (en) HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS
EP3638211A4 (en) PROLONGED DELAYED-RELEASE PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190820

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200618

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016471

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20240104BHEP

Ipc: A61P 9/12 20060101ALI20240104BHEP

Ipc: A61P 9/10 20060101ALI20240104BHEP

Ipc: A61P 43/00 20060101ALI20240104BHEP

Ipc: A61P 9/00 20060101ALI20240104BHEP

Ipc: A61P 3/04 20060101ALI20240104BHEP

Ipc: A61P 3/00 20060101ALI20240104BHEP

Ipc: A61P 1/16 20060101ALI20240104BHEP

Ipc: A61P 3/10 20060101ALI20240104BHEP

Ipc: A61P 1/00 20060101ALI20240104BHEP

Ipc: A61P 19/04 20060101ALI20240104BHEP

Ipc: A61P 3/06 20060101ALI20240104BHEP

Ipc: A61K 45/06 20060101ALI20240104BHEP

Ipc: A61K 31/192 20060101ALI20240104BHEP

Ipc: A61K 31/216 20060101AFI20240104BHEP

INTG Intention to grant announced

Effective date: 20240125

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031216000

Ipc: A61K0031426000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602018076686

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031216000

Ipc: A61K0031426000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20240606BHEP

Ipc: A61P 9/12 20060101ALI20240606BHEP

Ipc: A61P 9/10 20060101ALI20240606BHEP

Ipc: A61P 43/00 20060101ALI20240606BHEP

Ipc: A61P 9/00 20060101ALI20240606BHEP

Ipc: A61P 3/04 20060101ALI20240606BHEP

Ipc: A61P 3/00 20060101ALI20240606BHEP

Ipc: A61P 1/16 20060101ALI20240606BHEP

Ipc: A61P 3/10 20060101ALI20240606BHEP

Ipc: A61P 1/00 20060101ALI20240606BHEP

Ipc: A61P 19/04 20060101ALI20240606BHEP

Ipc: A61P 3/06 20060101ALI20240606BHEP

Ipc: A61K 45/06 20060101ALI20240606BHEP

Ipc: A61K 31/192 20060101ALI20240606BHEP

Ipc: A61K 31/426 20060101AFI20240606BHEP

INTG Intention to grant announced

Effective date: 20240619

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018076686

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20241219

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250103

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_148/2025

Effective date: 20250102

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 8

Effective date: 20250103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250121

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250131

26N No opposition filed

Effective date: 20250821